Molecular medicine

Ultrasound Neuromodulation Shows Promise to Treat Pulmonary Hypertension, Feinstein Institutes Research

Retrieved on: 
화요일, 5월 7, 2024
Health, Science, Radiology, Research, Cardiology, Brain, Cancer, Inflammation, Crohn's disease, Biomedical engineering, Cell, Pulmonary hypertension, American Heart Association, Woman, Blood, Vagus nerve stimulation, Autonomic nervous system, Inflammatory Bowel Diseases, Disease, Heart, Vagus nerve, Death, Diabetes, Interface (computing), Neuroscience, MD, PAH, Doctor of Philosophy, GE Research, Constriction, Spleen, VNS, Human, Sensation, Pressure, Circulation Research, Patient, Arthritis, Nervous system, Molecular medicine, Reflex, Medical research, Multimedia, Paralysis, Biomarker, Credit, Orthostatic hypertension, Heart failure, Medical imaging

Bioelectronic medicine scientists at The Feinstein Institutes for Medical Research used noninvasive, splenic focused ultrasound stimulation (sFUS) and found they can reduce inflammation and improve symptoms of pulmonary arterial hypertension (PAH).

Key Points: 
  • Bioelectronic medicine scientists at The Feinstein Institutes for Medical Research used noninvasive, splenic focused ultrasound stimulation (sFUS) and found they can reduce inflammation and improve symptoms of pulmonary arterial hypertension (PAH).
  • View the full release here: https://www.businesswire.com/news/home/20240507538578/en/
    Feinstein Institutes’ Dr. Stavros Zanos is the senior author on the new bioelectronic medicine ultrasound paper.
  • The research adds to the growing scientific evidence of bioelectronic medicine and neuromodulation as an effective therapy to treat diseases with an inflammatory component.
  • At the Feinstein Institutes, medical researchers use modern technology to develop new device-based therapies to treat disease and injury.

New Transformative Leadership Team Announced for Texas Children's World-Renowned Heart Center

Retrieved on: 
금요일, 5월 3, 2024
News, Pediatrics, Surgeon, Doctor of Philosophy, Bachelor of Science, Baylor University, Diagnosis, Texas Children's Hospital, Medical director, University, DRS, Ventricular septal defect, Baylor College of Medicine, Faculty, Moss, Royal Children, National university, Royal college, Executive, Hospital, Research, Monash University, Division, Congenital heart defect, Arrhythmia, Cardiomyopathy, NHS foundation trust, Evelina London Children's Hospital, Patient, Principal, Molecular medicine, Growth, Dentistry

Dr. Daniel Penny , previously Chief of Cardiology at Texas Children's Hospital, was recently named as Executive Co-Director of the Heart Center.

Key Points: 
  • Dr. Daniel Penny , previously Chief of Cardiology at Texas Children's Hospital, was recently named as Executive Co-Director of the Heart Center.
  • "We are incredibly proud to announce our new Heart Center executive leadership team," said Dr. Lara Shekerdemian , Pediatrician-In-Chief and chair of Pediatrics at Texas Children's Hospital.
  • "I am truly honored to join the leadership team at Texas Children's Heart Center," said Dr. Salih.
  • "For many decades now, Texas Children's Heart Center has cared for the world's rarest and most complex heart conditions.

Vagus nerve activation of the spleen shows promise to treat infections, Feinstein Institutes research

Retrieved on: 
금요일, 4월 26, 2024
Biotechnology, Managed Care, Health, General Health, Pharmaceutical, Health Technology, Other Science, Research, Hospitals, Science, Clinical Trials, Diamond, Autoantibody, Cancer, Bangladesh Technical Education Board, Inflammation, Biomedical engineering, National academy, National Academy of Sciences, Mouse, Crohn's disease, Pulmonary hypertension, Map, Science Advances, Vagus nerve stimulation, Inflammatory Bowel Diseases, Diabetes, Interface (computing), Neuroscience, Acetylcholine, Doctor of Philosophy, Spleen, VNS, DRS, Disease, Anatomy, Human, Sensation, Autoimmune disease, Nervous system, Arthritis, Molecular medicine, Physiology, Medicine, Immunology, Medical research, Multimedia, Lupus, Immune system, Antibody, Paralysis, Immunity, Credit, Autoimmunity, Sepsis, Vagus nerve, Vaccine

New research published in Science Advances by The Feinstein Institutes for Medical Research scientists shows that activation of the vagus nerve triggers the spleen, thereby regulating the production of antibodies.

Key Points: 
  • New research published in Science Advances by The Feinstein Institutes for Medical Research scientists shows that activation of the vagus nerve triggers the spleen, thereby regulating the production of antibodies.
  • This research highlights how the nervous system regulates immunity and suggests potential for non-pharmalogical, vagus nerve modulation to treat a variety of diseases, like lupus and sepsis.
  • Dr. Zanos’s research focus is on understanding the anatomy and physiology of the vagus nerve and the effects vagus nerve stimulation has in inflammation and cardiovascular diseases.
  • At the Feinstein Institutes, medical researchers use modern technology to develop new device-based therapies to treat disease and injury.

Feinstein Institutes’ Daniel A. Grande Named President-Elect of the International Cartilage Regeneration & Joint Preservation Society (ICRS)

Retrieved on: 
목요일, 4월 18, 2024
Health, Hospitals, Other Health, Other Science, General Health, Research, Science, Education, FDA, Rheumatology, EVS, Microsoft Exchange Server, Intervertebral disc, Regenerative medicine, Seminal vesicles, Cartilage, Doctor of Philosophy, B cell, Meniscus, ICRS, Patient, Tissue engineering, Molecular medicine, 3D bioprinting, Medical research, Microsoft Access, Multimedia, Regeneration, Stem cell, Credit, Journal, Medical device

The International Cartilage Regeneration & Joint Preservation Society (ICRS) has named Daniel A. Grande, PhD, assistant vice president of research services and professor of molecular medicine and orthopedic surgery at The Feinstein Institutes for Medical Research , its new President-Elect.

Key Points: 
  • The International Cartilage Regeneration & Joint Preservation Society (ICRS) has named Daniel A. Grande, PhD, assistant vice president of research services and professor of molecular medicine and orthopedic surgery at The Feinstein Institutes for Medical Research , its new President-Elect.
  • View the full release here: https://www.businesswire.com/news/home/20240418363701/en/
    Feinstein Institutes’ Dr. Daniel A. Grande has been named the new president-elect of International Cartilage Repair Society.
  • (Credit: Feinstein Institutes)
    Dr. Grande, renowned for his significant contributions to cartilage repair and regeneration, will lead the ICRS in its mission to advance science and education in preventing and treating cartilage injuries.
  • "I am honored and excited to serve as the President-Elect of the International Cartilage Regeneration & Joint Preservation Society.

ADARx Pharmaceuticals Appoints Dr. Chris Storgard as Chief Medical Officer

Retrieved on: 
화요일, 4월 2, 2024
Clinical research, Molecular medicine, AstraZeneca, Entrepreneurship, Patient, SAN, Mayo Clinic, Research, RNA, Bachelor of Science, Lead, University, MD, Senior, Sympathetic nervous system, Biology, Therapy, Destiny, Division, CMO, Amgen, DSM-IV codes, Pharmaceutical industry

SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a clinical stage biotechnology company developing next generation RNA therapeutics, today announced the appointment of Chris Storgard, M.D., as Chief Medical Officer (CMO).

Key Points: 
  • SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a clinical stage biotechnology company developing next generation RNA therapeutics, today announced the appointment of Chris Storgard, M.D., as Chief Medical Officer (CMO).
  • As CMO, Dr. Storgard will lead Clinical Research, Clinical Operations, Biometrics, Pharmacovigilance and Medical Affairs.
  • Dr. Storgard has a BSc in biology and an MD from the University of Saskatchewan in Canada.
  • Dr. Storgard completed a fellowship in rheumatology at Scripps Clinic and Research Center in San Diego, CA.

Feinstein Institutes Secures $6.1M NIH Grant for Red Cell Disorder Research

Retrieved on: 
수요일, 4월 3, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, Diamond, Molecular medicine, Sickle cell disease, Erythropoiesis, Hematology, HMGB1, Cell cycle, Mortality, Doctor of Philosophy, Quality of life, NIH, Diamond–Blackfan anemia, DBA, Credit, Lung, SCD, Medical research, Anemia, Bangladesh Technical Education Board, Multimedia, Conditional sentence, Pharmaceutical industry

To further our understanding and potential treatments of these disorders, The Feinstein Institutes for Medical Research has been awarded a $6.1 million grant from the National Institutes of Health (NIH).

Key Points: 
  • To further our understanding and potential treatments of these disorders, The Feinstein Institutes for Medical Research has been awarded a $6.1 million grant from the National Institutes of Health (NIH).
  • View the full release here: https://www.businesswire.com/news/home/20240403646471/en/
    Dr. Lionel Blanc will lead the new NIH-funded red cell disorders research (Credit: Feinstein Institutes)
    Led by Lionel Blanc, PhD , professor in the Institute of Molecular Medicine at the Feinstein Institutes, the seven-year initiative aims to build off previous research and will shed light on DBA, SCD and anemia.
  • “Understanding red cell blood disorders, how they develop and progress, is essential given their global impact on millions,” said Dr. Blanc.
  • In 2019, he received a $2.5 million grant from the NIH to study treatment for erythropoietic disorders, including DBA.

Agilent and UC San Diego Launch Center of Excellence in Cellular Intelligence

Retrieved on: 
화요일, 4월 2, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Health Technology, University, Education, Molecular medicine, Disease, RL, Agilent Technologies, UC, COE, Life, Immunity, Eukaryote, Mobile phone

(NYSE: A), a global leader in life sciences, diagnostics, and applied chemical markets, and the University of California San Diego (UC San Diego), one of the top-ranked public research universities in the world, today announced an innovative scientific collaboration to establish the Agilent Center of Excellence (CoE) in Cellular Intelligence .

Key Points: 
  • (NYSE: A), a global leader in life sciences, diagnostics, and applied chemical markets, and the University of California San Diego (UC San Diego), one of the top-ranked public research universities in the world, today announced an innovative scientific collaboration to establish the Agilent Center of Excellence (CoE) in Cellular Intelligence .
  • The Agilent CoE, located at UC San Diego’s School of Medicine, will foster collaboration and innovation among researchers from Agilent and UC San Diego, and other institutions and industry partners.
  • “We are thrilled to partner with Agilent to launch the Agilent CoE in Cellular Intelligence at UC San Diego, which will advance our understanding of the fundamental principles of life and the origin of biological complexity,” added Dr. Pradipta Ghosh, Professor of Medicine and Cellular and Molecular Medicine at UC San Diego and Founding Director of the program.
  • It combines experimental, computational, and theoretical approaches to decode the molecular and cellular mechanisms of these switch circuits and explore their implications for health and disease.

Bioelectronic medicine Feinstein Institutes researchers elected to AIMBE College of Fellows

Retrieved on: 
월요일, 3월 25, 2024
Health, Health Insurance, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Vagus nerve, Metabolism, Interdisciplinarity, Biomedical engineering, Brain, Sepsis, Rheumatoid arthritis, Medicine, Mevalonate pathway, Interface (computing), Communication, International Society, Disease, Paralysis, Diabetes, Education, Inflammation, Pulmonary hypertension, Nervous system, Class, PNAS, Cancer, Neuroscience, Doctor of Philosophy, AIMBE, Neuron, Inflammatory Bowel Diseases, Arthritis, Credit, Northwell Health, American Institute, Molecular medicine, Sensation, Infection, DRS, Immune system, Injury, Medical research, Inflammatory bowel disease, Biology, Multimedia, National academy, Government, ISAN, Medical device

The American Institute for Medical and Biological Engineering (AIMBE) has announced the election of two researchers from The Feinstein Institutes for Medical Research to the AIMBE College of Fellows Class of 2024 for their contributions to the fields of medical and biological engineering, and particularly the field of bioelectronic medicine.

Key Points: 
  • The American Institute for Medical and Biological Engineering (AIMBE) has announced the election of two researchers from The Feinstein Institutes for Medical Research to the AIMBE College of Fellows Class of 2024 for their contributions to the fields of medical and biological engineering, and particularly the field of bioelectronic medicine.
  • Valentin Pavlov, PhD , and Sangeeta Chavan, PhD , both professors in the Institute of Bioelectronic Medicine , were recognized in-person during the AIMBE Annual Event in Washington D.C..
  • Sangeeta Chavan (left) and Valentin Pavlov (right) have been elected to the AIMBE College of Fellows for advancing the fields of medical and biological engineering.
  • On behalf of the Feinstein Institutes and Northwell Health, we congratulate them.”
    The Feinstein Institutes for Medical Research is the global scientific home of bioelectronic medicine where medical researchers use modern technology to develop new device-based therapies to treat disease and injury.

OncoOne Announces Formation of Clinical Advisory Board to Support Development of ON104 for Chronic Inflammatory Diseases

Retrieved on: 
화요일, 3월 12, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, European Alliance, United, United Nations, Asthma, AAP, Yale school, CD74, Hôpital Cochin, Trinity College Dublin, Arthritis & Rheumatology, Molecular medicine, Cancer, University, Publication, Medical school, ASCI, Prognosis, Trinity, Pathology, Diagnosis, Public health, Trinity College, Arthritis, Physiology, Biomarker, Global Health, Nephritis, Society, EULAR, Inflammatory bowel disease, Physician, Pharmaceutical industry

OncoOne , a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced today the formation of a clinical advisory board to provide strategic and clinical insights for the company’s lead program in immunology, ON104.

Key Points: 
  • OncoOne , a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced today the formation of a clinical advisory board to provide strategic and clinical insights for the company’s lead program in immunology, ON104.
  • ON104 is a monoclonal antibody targeting the oxidized isoform of the macrophage migration inhibitory factor (oxMIF) for the treatment of chronic inflammatory diseases.
  • His research focuses on arthritis and other inflammatory rheumatic diseases, precision medicine, and the management of complex diseases.
  • Dr. Freissmuth is an inaugural member of OncoOne’s scientific advisory board, where he continues to support the development of the company’s pipeline of biotherapeutics.

BostonGene Bolsters Leadership Team to Accelerate Innovation and Growth

Retrieved on: 
목요일, 2월 22, 2024
Health, Genetics, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Wake Forest University, Cambia Health Solutions, Senior, Doctor of Philosophy, RingCentral, Small business, Georgetown University, Medical director, Record, Molecular medicine, Drug development, Hospital, Radiology, Beyond Meat, MBA, MGH, Stanford University, University, Pathology, Associate, Patient, Intuit, Goldman Sachs, RPX, Massachusetts General Hospital, Harvard Medical School, Helmy Eltoukhy, Cancer, Management

"On behalf of the BostonGene Board of Directors, I am thrilled to welcome Joe, Mark, and Ned to our team," said Andrew Feinberg, President and CEO of BostonGene.

Key Points: 
  • "On behalf of the BostonGene Board of Directors, I am thrilled to welcome Joe, Mark, and Ned to our team," said Andrew Feinberg, President and CEO of BostonGene.
  • Dr. Lennerz received an MD and a PhD in molecular medicine from the University of Erlangen, Germany.
  • "I am delighted to join BostonGene at such a pivotal moment in its trajectory.
  • In addition to BostonGene, Ned is a board member at RingCentral and Beyond Meat.